BIO-RAD LABORATORIES, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.16B | $2.07B | $2.02B | $2.18B | $2.13B | $2.07B | $2.07B | $1.93B |
| Cost of Revenue | $972.5M | $929.7M | $897.8M | $996.5M | $954.2M | $914.1M | $894.7M | $835.6M |
| Gross Profit | $1.19B | $1.14B | $1.12B | $1.18B | $1.18B | $1.16B | $1.18B | $1.09B |
| Gross Margin | 55.0% | 55.0% | 55.5% | 54.2% | 55.3% | 55.8% | 56.9% | 56.6% |
| Operating Expenses | ||||||||
| Research & Development | $250.2M | $205.7M | $193.0M | $220.3M | $211.0M | $209.2M | $177.6M | $172.3M |
| SG&A Expense | $806.8M | $814.7M | $762.0M | $808.2M | $798.1M | $681.8M | $696.0M | $635.2M |
| Operating Income | $119.3M | $55.7M | $166.7M | $150.0M | $169.5M | $264.2M | $305.2M | $284.0M |
| Operating Margin | 5.5% | 2.7% | 8.3% | 6.9% | 7.9% | 12.8% | 14.7% | 14.7% |
| Interest Expense | $23.0M | $23.4M | $21.7M | $22.1M | $61.3M | $51.1M | $53.1M | $63.7M |
| Pretax Income | $97.8M | $41.6M | $145.8M | $131.6M | $112.4M | $229.9M | $245.8M | $220.3M |
| Income Tax Expense | $-24.4M | $15.6M | $36.6M | $42.7M | $34.6M | $64.4M | $67.0M | $33.3M |
| Net Income | $122.2M | $26.0M | $109.2M | $88.8M | $77.8M | $165.5M | $179.0M | $185.5M |
| Net Margin | 5.7% | 1.3% | 5.4% | 4.1% | 3.6% | 8.0% | 8.6% | 9.6% |
| EPS (Basic) | $4.12 | $0.88 | $3.74 | $3.08 | $2.72 | $5.85 | $6.39 | $6.70 |
| EPS (Diluted) | $4.07 | $0.88 | $3.71 | $3.05 | $2.69 | $5.78 | $6.29 | $6.59 |
| Shares Outstanding (Basic) | 29.7M | 29.4M | 29.2M | 28.9M | 28.6M | 28.3M | 28.0M | 27.7M |
| Shares Outstanding (Diluted) | 30.0M | 29.6M | 29.4M | 29.1M | 28.9M | 28.6M | 28.5M | 28.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |